Monoclonal antibodies could play a vital role in the battle against COVID-19. To date, such infusion-delivered antibodies from Eli Lilly (NYSE:LLY) and Regeneron Pharmaceuticals (NSDQ:REGN) have received emergency use authorization from FDA.  Now, a phase 2/3 clinical trial will study the potential of investigational monoclonal antibody therapy for patients with mild-to-moderate COVID-19.  The antibodies, known…